Literature DB >> 11432109

Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryo transfer.

J N Hugues1, H Bry-Gauillard, B Bständig, M Uzan, I Cedrin-Durnerin.   

Abstract

PURPOSE: To compare the efficiency and efficacy of two recombinant human FSH (r-FSH) and urinary (u-FSH) preparations in patients undergoing superovulation for IVF-ET using a short-term gonadotropin releasing hormone agonist (GnRH-a) (Triptorelin) protocol.
METHODS: A total of 88 women undergoing IVF-ET were included in this prospective study. They were randomized to receive u-FSH (150 IU/d), follitropin-alpha (100 IU/d), or follitropin-beta (100 IU/d) for 2 days, and dosages were subsequently adjusted according to the ovarian response.
RESULTS: The FSH dose required for the overall stimulation was significantly lower in patients treated with r-FSH than in those treated with u-FSH while serum FSH values were higher in the latter group. There were no statistically significant differences in ovarian response and IVF outcome between r-FSH preparations.
CONCLUSIONS: Recombinant FSH preparations have a higher efficiency than urinary ones in patients undergoing IVF-ET using a short-term GnRH-a protocol. In this situation, the two recombinant follitropins have comparable effectiveness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432109      PMCID: PMC3455363          DOI: 10.1023/a:1009408029509

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  14 in total

1.  Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction.

Authors:  S Daya; J Gunby
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

2.  Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta.

Authors:  J Harlin; G Csemiczky; H Wramsby; G Fried
Journal:  Hum Reprod       Date:  2000-02       Impact factor: 6.918

3.  Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.

Authors:  F Raga; F Bonilla-Musoles; E M Casañ; F Bonilla
Journal:  Hum Reprod       Date:  1999-06       Impact factor: 6.918

4.  EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. CPMP Working Party on Efficacy of Medicinal Products.

Authors: 
Journal:  Pharmacol Toxicol       Date:  1990-10

5.  A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer.

Authors:  P Brinsden; F Akagbosu; L M Gibbons; S Lancaster; D Gourdon; P Engrand; E Loumaye
Journal:  Fertil Steril       Date:  2000-01       Impact factor: 7.329

6.  Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins.

Authors:  H J Out; S G Driessen; B M Mannaerts; H J Coelingh Bennink
Journal:  Fertil Steril       Date:  1997-07       Impact factor: 7.329

7.  Genetic engineering of human FSH (Gonal-F).

Authors:  C M Howles
Journal:  Hum Reprod Update       Date:  1996 Mar-Apr       Impact factor: 15.610

8.  Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.

Authors:  M Tulppala; M Aho; T Tuuri; S Vilska; T Foudila; T Hakala-Ala-Pietilä; J Moilanen; T Bützow; S Kaukoranta; V Söderström-Anttila; R Siegberg; A M Suikkari; O Hovatta
Journal:  Hum Reprod       Date:  1999-11       Impact factor: 6.918

Review 9.  Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon).

Authors:  W Olijve; W de Boer; J W Mulders; P M van Wezenbeek
Journal:  Mol Hum Reprod       Date:  1996-05       Impact factor: 4.025

10.  A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.

Authors:  E H Hoomans; A N Andersen; A Loft; R A Leerentveld; A A van Kamp; H Zech
Journal:  Hum Reprod       Date:  1999-10       Impact factor: 6.918

View more
  3 in total

1.  The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.

Authors:  Chunxia Yang; Naijun Dong; Feng Li; Yurong Ji; Yu Pan; Hong She
Journal:  J Ovarian Res       Date:  2022-06-21       Impact factor: 5.506

2.  Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis.

Authors:  Alberto Revelli; Francesca Poso; Gianluca Gennarelli; Federica Moffa; Giuseppina Grassi; Marco Massobrio
Journal:  Reprod Biol Endocrinol       Date:  2006-07-18       Impact factor: 5.211

Review 3.  Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis.

Authors:  E M Bordewijk; F Mol; F van der Veen; M Van Wely
Journal:  Hum Reprod Open       Date:  2019-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.